



Our STN: BL 125813

**MID-CYCLE COMMUNICATION  
SUMMARY**  
MAY 22, 2024

Autolus, Inc.  
Attention: Nirav Patel  
15810 Gaither Drive,  
Suite 230  
Gaithersburg, MD 20877

Dear Nirav Patel:

Attached is a copy of the summary of your May 15, 2024, Mid-Cycle Communication Teleconference with CBER. This memorandum constitutes the official record of the Teleconference. If your understanding of the Teleconference outcomes differs from those expressed in this summary, it is your responsibility to communicate with CBER as soon as possible.

Please include a reference to STN BL 125813 in your future submissions related to obecabtagene autoleucel.

If you have any questions, please contact Danielle Bauman at (301) 796 – 4501 or by email at [Danielle.Bauman@fda.hhs.gov](mailto:Danielle.Bauman@fda.hhs.gov).

Sincerely,

Beatrice Kallungal, MS  
Director  
Division of Review Management and Regulatory Review 1  
Office of Review Management and Regulatory Review  
Office of Therapeutic Products  
Center for Biologics Evaluation and Research

## Mid-Cycle Communication Teleconference Summary

**Application Type and Number:** BLA 125813  
**Product Name:** obecabtagene autoleucel (obe-cel)  
**Proposed Indication for Use:** Treatment of Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL)  
**Applicant:** Autolus Inc  
**Meeting Date & Time:** May 15, 2024 – 10:00am – 11:00am  
**Committee Chair:** Andrew Timmons, PhD  
**RPM:** Danielle Bauman, MPH

### FDA Attendees:

Meghna Alimchandani, MD, CBER/OBPV/DPV  
Danielle Bauman, MPH, CBER/OTP/ORMRR  
Najat Bouchkouj, MD, CBER/OTP/OCE  
Juliane Carvalho, MS, RAC, CBER/OTP/ORMRR  
Jessica Chery, PhD, CBER/OTP/OGT  
Denise Gavin, PhD, CBER/OTP/OGT  
Jana Highsmith, CBER/OCBQ/DMPQ  
Alicia Howard, CBER/OCBQ/DBSQC  
Kula Jha, PhD, CBER/OCBQ/DMPQ  
Kathleen Jones, PhD, CBER/OCBQ/DMPQ  
Timothy Kamalidinov, PhD, CBER/OTP/OGT  
Beatrice Kallungal, MS, CBER/OTP/ORMRR  
Nicole Li, CBER/OCBQ/DMPQ  
Lori Peters, CBER/OCBQ/DMPQ  
Donna Przepiorka, MD, PhD, CDER/OND/ODD/DHMI  
Carolyn Renshaw, CBER/OCBQ/DMPQ  
Andrey Sarafanov, PhD CBER/OTP/OPPT/DH/HB2  
Anurag Sharma, PhD, CBER/OTP/OGT  
Ramani Sista, PhD, CBER/OTP/ORMRR  
Deborah Thompson, MD, MSPH, CBER/OBPV/DPV  
Andrew Timmons, PhD, CBER/OTP/OGT  
Nicole Verdun, MD, CBER/OTP  
Nancy Waites, MS, CBER/OCBQ/DMPQ  
Xiaofei Wang, PhD, CBER/OTP/OCE  
Kerry Welsh, CBER/OBPV/DPV  
Zhenzhen Xu, PhD, CBER/OBPV/DB

### Autolus Attendees:

Wolfram Brugger, VP, Head of Clinical Development  
Michael Zhang, VP, Head of Biometrics  
Mohammad Khalil, VP, Drug Safety & Pharmacovigilance  
Michael Merges, VP, Analytical Development and Quality Control  
Eaine Dymond, VP, Quality Leadership  
Markus Gruell, VP, Head of Quality

Koki Lilova, Executive Director, Cell Process Development  
Mei Mei Fung, Senior Director, Production & MSAT  
Andrea Braun, VP, Head of Global Regulatory Affairs  
Anju Mahesh, Executive Director, Head of CMC Regulatory Affairs  
Nirav Patel, Sr Director, Regulatory Affairs  
Miranda Neville, SVP, Program and Portfolio Management  
Edgar Braendle, Consultant, Clinical Development

**Discussion Summary:**

1. Any significant issues/major deficiencies, categorized by discipline, identified by the Review Committee to date.
  - No significant issues/major deficiencies at this time
  - Review of clinical efficacy and safety data is ongoing.
    - Review issues will be communicated through information requests (IRs) and during labeling negotiations.
    - Notably, the efficacy section of the label (Section 14) will be revised to reflect FDA-adjudicated responses (as previously communicated in prior IRs) and using complete response within 3 months of infusion as the basis for efficacy.

2. Information regarding major safety concerns.

There are no major safety concerns at this time

3. Preliminary Review Committee thinking regarding a.) risk management, b) the potential need for any post-marketing requirement(s) (PMRs), and/or safety-related PMCs, and c.) the ability of adverse event reporting and CBER's Sentinel Program to provide sufficient information about product risk.

Review of the pharmacovigilance plan and protocol synopsis for the postmarketing long-term follow-up registry study are ongoing. We will communicate in the future if other safety concerns arise.

4. Any information requests sent, and responses not received.

All responses through May 13, 2024, have been submitted by the Applicant and received by the Agency.

5. Any new information requests to be communicated.

Pharmacovigilance, DMPQ, Chemistry, Manufacturing, and Controls (CMC), and Clinical information requests will be sent as needed.

6. Proposed date(s) for the Late-Cycle meeting (LCM).

- The Late-Cycle Meeting between the Applicant and the Review Committee is currently scheduled for August 2, 2024 at 12:00 pm ET
- The Agency intends to send the LCM meeting materials approximately 10 days in advance of the LCM.
- If these timelines change, it will be communicated during the course of the review.

7. Updates regarding plans for the AC meeting.

There is no AC meeting planned at this time.

8. Other projected milestone dates for the remainder of the review cycle, including changes to previously communicated dates.

- Applicant Late-cycle Meeting | 12:00 pm ET - August 2, 2024
- Communicate Anticipated PMRs | September 20, 2024
- Communicate Proposed Labeling and PMCs | October 17, 2024
- PDUFA Action Due Date | November 17, 2024

9. Discuss status of inspections (GMP, BiMo, GLP) including issues identified that could prevent approval.

- No additional manufacturing inspections planned at this time
- No inspection issues identified at this time that could prevent approval

### **Discussion Summary:**

1. Can the Agency please provide an update on the review of our proposed REMS for obelcel?
  - The review of Pharmacovigilance Plan is under review including post-marketing studies and REMS
  - There have been changes to REMS for CAR-T products. Agency will engage with Applicant further on this.

2. Can the Agency please provide an update on the progress of CMC and DMPQ review so far, particularly in relation to the anticipated topics leading up to the late cycle meeting on August 2, 2024?
  - CMC:
    - CMC stated that the review is ongoing, and that issues will be addressed via IRs and/or informal teleconferences as they arise in the course of the review.
    - CMC confirmed that, upon completing the review of the proposed commercial acceptance criteria for the lentiviral vector (LVV) and drug product (DP), the Agency will communicate with Applicant if any acceptance criteria need to be revised based on the available data.
    - CMC reiterated that, per the pre-BLA meeting summary, any supplemental stability data should be provided to the BLA no later than 60 days prior to the action due date to be considered in the establishment of the stability shelf life for the LVV and DP.
  - DMPQ
    - Review is ongoing, IRs will be sent as needed.
    - Response to the FDA 483 is still under review and will contact the Applicant as needed.
3. Are there any updates on early approval?
  - The Action Due Date is November 17, 2024.